The Cumulative Chemical Exposome, Epigenetic Programming, and the Non-communicable Disease Transition in Sub-saharan Africa

Abstract Background Sub-Saharan Africa (SSA) is confronting a rapidly rising burden of non-communicable diseases (NCDs). The dominant attribution of these trends to lifestyle changes, however, is conceptually incomplete. Parallel to dietary changes, the food systems and broader consumer environment have undergone a dramatic and largely unmonitored chemical intensification, introducing a complex, population-wide chemical exposure burden with plausible mechanistic links to every major NCD category. In this hypothesis-driven narrative review, we integrate evidence across several exposure domains to construct a layered chemical exposome with direct relevance to the broader SSA region. Methods A systematic search of peer-reviewed databases (no date restrictions) was supplemented by grey literature from regulatory bodies, and IARC and WHO technical reports. Ghana-specific and SSA-specific data were prioritized. Where appropriate, experimental animal and cell-line evidence was incorporated to support mechanistic plausibility. Results Multiple chemical exposure classes converge on a limited set of shared biological pathways: endocrine disruption, oxidative stress and chronic inflammation, genotoxicity, and epigenetic dysregulation. A central contribution of this review is that we highlight the epigenetic consequences of the chemical burden which may be transmissible across generations, offering a mechanistic explanation for why Ghana's NCD transition is occurring faster, at younger ages, and across broader socioeconomic strata than lifestyle models predict. A five-hit model maps these exposures to NCD outcomes across the life course. Conclusions The chemical exposome represents a major, systematically underestimated driver of the NCD transition in SSA. Priority interventions include elimination of acute chemical hazards, identification and tighter regulation of embedded everyday sources of endocrine disruptors and other environmental toxicants, integration of exposure mitigation with clinical protocols, and investment in biomonitoring infrastructure capable of detecting epigenetic and transgenerational exposure effects. Protecting current populations from chemical exposome harm is critical to protecting the health of subsequent generations.